ECMELLA vs. ECMO on 30-day Mortality
Treatment With Leftventricular Impella® Micro-axial Pump and Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) During Extracorporeal Cardiopulmonary Resuscitation (eCPR) on Mortality - An International Multicenter Cohort Study
1 other identifier
observational
60
1 country
1
Brief Summary
This international, multicenter cohort study aims to investigate outcomes after treatment with extracorporeal cardiopulmonary resuscitation (eCPR) during cardiac arrest.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 27, 2021
CompletedFirst Posted
Study publicly available on registry
January 4, 2022
CompletedStudy Start
First participant enrolled
February 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2022
CompletedJanuary 4, 2022
December 1, 2021
8 months
October 27, 2021
December 14, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
30-day mortality
Mortality within 30 days after cardiac arrest event.
Mortality within 30 days after cardiac arrest event.
Secondary Outcomes (2)
Hospital length of stay
Through study completion - an average of 1 year.
Intensive Care Unit (ICU) length of stay
Through study completion - an average of 1 year.
Study Arms (2)
VA-ECMO
Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest.
ECMELLA
Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella® micro-axial pump.
Interventions
Eligibility Criteria
Adult patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or VA-ECMO and Impella (so called "ECMELLA") during extracorporeal cardiopulmonary resuscitation.
You may qualify if:
- Adult patients
- Cardiac arrest
- Treatment with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or "ECMELLA" (that is VA-ECMO plus left ventricular Impella® micro-axial pump)
You may not qualify if:
- Non-adult patients
- No treatment with VA-ECMO or "ECMELLA"
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Charité - Universitätsmedizin Berlin
Berlin, 12203, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Carsten Skurk, MD
Charite University
- PRINCIPAL INVESTIGATOR
Tharusan Thevathasan, MD
Charite University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 27, 2021
First Posted
January 4, 2022
Study Start
February 1, 2022
Primary Completion
October 1, 2022
Study Completion
November 1, 2022
Last Updated
January 4, 2022
Record last verified: 2021-12
Data Sharing
- IPD Sharing
- Will not share